hVIVO surges 50% in two days as ILiAD funding boosts contract hopes

hVIVO shares rallied 50% over two days to 9.13p after ILiAD Biotechnologies raised $115m in an oversubscribed Series B led by RA Capital, increasing the likelihood that a January 2025 letter of intent will convert into a full contract to run a pivotal phase III human challenge trial for the BPZE1 intranasal pertussis vaccine. Stifel notes the financing removes a key hurdle, estimates the potential contract at about £15m (not included in hVIVO’s £40m order book) and retains a 'hold' rating with a 10p price target, saying formal contract confirmation would help underpin 2026 revenue guidance.

Analysis

Market structure: The immediate winners are hVIVO (AIM:HVO) equity holders and specialized human challenge CROs; ILiAD and its investors (RA Capital, Janus Henderson) also gain optionality. A potential £15m contract is material (≈37.5% of hVIVO’s £40m order book) and would boost 2026 revenue guidance, increasing hVIVO’s pricing power for bespoke challenge trials while pressuring generalist CROs that lack niche challenge infrastructure.

Risk assessment: Key tail risks are non‑conversion of the LOI, trial approval delays by MHRA/EMA, or ILiAD program setbacks — any of which could erase recent gains ( >50% move). Imminent (days–weeks) risk is event-driven volatility; medium term (1–6 months) depends on contract signature/milestones; long term (6–24 months) depends on ILiAD clinical success and recurring challenge-trial demand. Hidden dependency: hVIVO’s near-term cash flow improvement hinges on milestone timing and payment structure, not just contract headline.

Trade implications: Direct play — tactical long in HVO sized 2–3% of portfolio conditional on contract confirmation within 60 days; hedge market beta by pairing long HVO with a 0.5–1% short position in the FTSE AIM All‑Share ETF. If liquid, use a 3‑month call spread (buy 8p, sell 14p) to cap cost and target 40–80% ROI if contract is announced. Rotate: increase exposure to specialized infectious-disease/biotech names on confirmed deals; reduce broad early-stage biotech exposure until regulatory clarity.

Contrarian angles: The market may be overpricing conversion probability — a £15m contract justifies upside but not a 50% two‑day rally unless milestones are front‑loaded. Historical parallels show many LOIs fail to become lucrative contracts; concentration risk (single-customer dependency) could magnify downside. Watch for contractual clauses (cancellation, milestone timing) and ILiAD clinical readouts over the next 30–90 days as the true valuation drivers.

Key Decisions for Investors

• Establish a tactical long position in AIM:HVO equal to 2–3% of portfolio size (or notional) with a hard stop at 6p and a take-profit tranche at 10p; increase to 4–5% only on definitive contract announcement within 60 days.
• If liquid, implement a 3‑month call spread on HVO (buy 8p call, sell 14p call) sized to equal a 1–2% portfolio exposure to cap premium and target asymmetric upside on contract confirmation; if options illiquid, use the equity with the hedge below.
• Pair trade: long HVO (as above) paired with a 0.5–1% short position in FTSE AIM All‑Share ETF (to hedge small‑cap beta) until ILiAD contract/milestones are public within 30–90 days.
• Reduce broad early‑stage infectious disease exposure by 1–2% in favor of specialized CRO exposure only after confirming contract terms; re‑assess if ILiAD or hVIVO disclose milestone timings within 30 days.
• Monitor specific triggers: demand definitive contract within 60 days, MHRA/EMA trial approval notices, and ILiAD milestone payment schedule; if no confirmation in 90 days, exit HVO positions entirely due to single‑contract concentration risk.